The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination.

Journal Article (Journal Article)

Development of effective human immunodeficiency virus 1 (HIV-1) vaccines requires synergy between innate and adaptive immune cells. Here we show that induction of the transcription factor CREB1 and its target genes by the recombinant canarypox vector ALVAC + Alum augments immunogenicity in non-human primates (NHPs) and predicts reduced HIV-1 acquisition in the RV144 trial. These target genes include those encoding cytokines/chemokines associated with heightened protection from simian immunodeficiency virus challenge in NHPs. Expression of CREB1 target genes probably results from direct cGAMP (STING agonist)-modulated p-CREB1 activity that drives the recruitment of CD4+ T cells and B cells to the site of antigen presentation. Importantly, unlike NHPs immunized with ALVAC + Alum, those immunized with ALVAC + MF59, the regimen in the HVTN702 trial that showed no protection from HIV infection, exhibited significantly reduced CREB1 target gene expression. Our integrated systems biology approach has validated CREB1 as a critical driver of vaccine efficacy and highlights that adjuvants that trigger CREB1 signaling may be critical for efficacious HIV-1 vaccines.

Full Text

Duke Authors

Cited Authors

  • Tomalka, JA; Pelletier, AN; Fourati, S; Latif, MB; Sharma, A; Furr, K; Carlson, K; Lifton, M; Gonzalez, A; Wilkinson, P; Franchini, G; Parks, R; Letvin, N; Yates, N; Seaton, K; Tomaras, G; Tartaglia, J; Robb, ML; Michael, NL; Koup, R; Haynes, B; Santra, S; Sekaly, RP

Published Date

  • October 2021

Published In

Volume / Issue

  • 22 / 10

Start / End Page

  • 1294 - 1305

PubMed ID

  • 34556879

Pubmed Central ID

  • PMC8525330

Electronic International Standard Serial Number (EISSN)

  • 1529-2916

Digital Object Identifier (DOI)

  • 10.1038/s41590-021-01026-9


  • eng

Conference Location

  • United States